title: Somatostatin Analogs and Tumor Localization Do Not Influence Vitamin D Concentration in Patients with Neuroendocrine Tumors.
abstract: Patients with neuroendocrine tumors (NETs), malignancies of rare but still rising incidence, may be a group at higher risk of vitamin D insufficiency. The gastrointestinal tumor prevalence and somatostatin analog (SSA) therapy may cause vitamin D malabsorption. The aim of this study was to evaluate the serum level of vitamin D in NET patients. A total of 36 NET patients were enrolled into the experimental group and 16 individuals were enrolled into the control group. All patients were further classified into subgroups according to primary tumor localization (gastropancreatic, lung, and other NETs) or therapy (with or without SSA treatment). The concentrations of total 25(OH)D were assayed with Electrochemiluminescence immunoassay (ECLIA). Serum concentration of 25(OH)D in NET patients did not differ significantly from that of the control group. However, the average level of 25(OH)D in both groups met the criteria of vitamin D deficiency. Importantly, SSA therapy did not aggravate vitamin D deficiency. Moreover, the concentration of 25(OH)D in the studied group was not significantly influenced by primary tumor localization, patient age, or season. Vitamin D deficiency is a widespread disorder affecting both NET patients and individuals without other health problems, and SSA and gastrointestinal tumor localization do not exacerbate this condition.
authors.affiliation: a Department of Immunoendocrinology , Chair of Endocrinology, Medical University of Lodz , Lodz , Poland.
authors.forename: Ewelina
authors.initials: E
authors.lastname: Motylewska
authors.affiliation: a Department of Immunoendocrinology , Chair of Endocrinology, Medical University of Lodz , Lodz , Poland.
authors.forename: Joanna
authors.initials: J
authors.lastname: Gawronska
authors.affiliation: a Department of Immunoendocrinology , Chair of Endocrinology, Medical University of Lodz , Lodz , Poland.
authors.forename: Agata
authors.initials: A
authors.lastname: Niedziela
authors.affiliation: a Department of Immunoendocrinology , Chair of Endocrinology, Medical University of Lodz , Lodz , Poland.
authors.forename: Gabriela
authors.initials: G
authors.lastname: Melen-Mucha
authors.affiliation: a Department of Immunoendocrinology , Chair of Endocrinology, Medical University of Lodz , Lodz , Poland.
authors.forename: Hanna
authors.initials: H
authors.lastname: Lawnicka
authors.affiliation: b Department of Clinical Endocrinology , Chair of Endocrinology, Medical University of Lodz , Lodz , Poland.
authors.forename: Jan
authors.initials: J
authors.lastname: Komorowski
authors.affiliation: c Department of Neuroendocrinology , Medical University of Lodz , Lodz , Poland.
authors.forename: Jacek
authors.initials: J
authors.lastname: Swietoslawski
authors.affiliation: a Department of Immunoendocrinology , Chair of Endocrinology, Medical University of Lodz , Lodz , Poland.
authors.forename: Henryk
authors.initials: H
authors.lastname: Stepien
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002117:Calcitriol / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000097:blood* / Q000473:pathology; D015282:Octreotide / Q000009:adverse effects* / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000009:adverse effects* / Q000627:therapeutic use; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014807:Vitamin D / Q000097:blood*; D014808:Vitamin D Deficiency / Q000097:blood / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D014807:Vitamin D; D013004:Somatostatin; D002117:Calcitriol; D015282:Octreotide